GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KPC Pharmaceuticals Inc (SHSE:600422) » Definitions » Debt-to-Revenue

KPC Pharmaceuticals (SHSE:600422) Debt-to-Revenue : 0.07 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is KPC Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

KPC Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ¥738 Mil. KPC Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ¥95 Mil. KPC Pharmaceuticals's annualized Revenue for the quarter that ended in Dec. 2024 was ¥11,776 Mil. KPC Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.07.


KPC Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for KPC Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KPC Pharmaceuticals Debt-to-Revenue Chart

KPC Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.10 0.14 0.11 0.10

KPC Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.12 0.13 0.11 0.07

Competitive Comparison of KPC Pharmaceuticals's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KPC Pharmaceuticals's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where KPC Pharmaceuticals's Debt-to-Revenue falls into.



KPC Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

KPC Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(738.427 + 94.641) / 8401.447
=0.10

KPC Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(738.427 + 94.641) / 11775.968
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


KPC Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of KPC Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


KPC Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
Executives
Qu Xiao Ru senior management
Xie Bo senior management
Meng Li senior management
Zhong Xiang Gang senior management
Wu Sheng Long senior management
Liu Jun Feng senior management
Wang Lei senior management
Zhang Meng Xun senior management
Hu Zhen Bo senior management
Sun Lei senior management
Xu Chao Neng senior management
Wang Jun senior management
Zhao Jian senior management
He Qin Director
Dai Xiao Chang senior management

KPC Pharmaceuticals Headlines

No Headlines